Edwards Lifesciences Corp
Ownership
Ownership Structure
Who owns Edwards Lifesciences Corp (EW)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.7% of the shares are freely tradable; institutional investors hold 94.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 9.12 | 52,590,933 | +0.2 | 03/31/2026 |
| Vanguard Capital Management, LLC | 6.55 | 37,727,792 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.58 | 26,407,018 | +0.0 | 03/31/2026 |
| State Street Corp | 4.56 | 26,296,399 | +1.2 | 03/31/2026 |
| JPMorgan Chase & Co | 3.77 | 21,744,712 | -16.4 | 03/31/2026 |
| Wellington Management Company LLP | 2.92 | 16,827,967 | -23.5 | 06/30/2026 |
| Bank of New York Mellon Corp | 2.90 | 16,737,548 | -4.3 | 03/31/2026 |
| FMR Inc | 2.52 | 14,503,770 | -12.5 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.18 | 18,335,292 | +0.3 | 07/31/2026 |
| Vanguard 500 Index Investor | 2.62 | 15,113,506 | +1.1 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | 43,926 | 3,874,273 $ | Sep 11, 2026 | direct |
| Lippis Daniel J. | CVP, TAVR | 40,034 | 3,530,991 $ | Sep 11, 2026 | direct |
| Markowitz Wayne | CVP, JAPAC | 19,371 | 1,708,483 $ | Sep 14, 2026 | direct |
| Bruls Annette | CVP, EMEACLA | 17,984 | 1,586,189 $ | Aug 28, 2026 | direct |
| Dahl Andrew M. | SVP, Corporate Controller | 14,615 | 1,289,079 $ | Sep 13, 2026 | direct |
| Zovighian Bernard J | CEO | 8,916 | 786,360 $ | Jul 27, 2026 | indirect |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Markowitz Wayne | CVP, JAPAC | Other | 568 | 84.37 | 47,922 |
| Sep 13, 2026 | Dahl Andrew M. | SVP, Corporate Controller | Other | 253 | 84.37 | 21,346 |
| Sep 11, 2026 | Markowitz Wayne | CVP, JAPAC | Other | 355 | 86.77 | 30,803 |
| Sep 11, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | Other | 398 | 86.77 | 34,534 |
| Sep 11, 2026 | Lippis Daniel J. | CVP, TAVR | Sell | 619 | 87.51 | 54,169 |
| Sep 11, 2026 | Lippis Daniel J. | CVP, TAVR | Other | 619 | 72.68 | 44,989 |
| Aug 31, 2026 | Dahl Andrew M. | SVP, Corporate Controller | Sell | 544 | 91.06 | 49,534 |
| Aug 28, 2026 | Bruls Annette | CVP, EMEACLA | Sell | 2,644 | 89.98 | 237,907 |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | Sell | 30,646 | 90.99 | 2,788,547 |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | Sell | 1,154 | 91.76 | 105,893 |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | Other | 31,800 | 72.68 | 2,311,224 |
| Aug 26, 2026 | Markowitz Wayne | CVP, JAPAC | Sell | 1,240 | 91.47 | 113,417 |
| Aug 11, 2026 | Lippis Daniel J. | CVP, TAVR | Sell | 619 | 92.03 | 56,967 |
| Aug 11, 2026 | Lippis Daniel J. | CVP, TAVR | Other | 619 | 72.68 | 44,989 |
| Jul 30, 2026 | Markowitz Wayne | CVP, JAPAC | Sell | 146 | 86.03 | 12,561 |
| Jul 28, 2026 | Markowitz Wayne | CVP, JAPAC | Sell | 9,628 | 85.06 | 818,958 |
| Jul 28, 2026 | Markowitz Wayne | CVP, JAPAC | Other | 9,628 | 74.02 | 712,665 |
| Jul 27, 2026 | Zovighian Bernard J | CEO | Sell | 2,921 | 83.93 | 245,172 |
| Jul 27, 2026 | Zovighian Bernard J | CEO | Other | 320 | 0.00 | – |
| Jul 11, 2026 | Bruls Annette | CVP, EMEACLA | Other | 109 | 92.21 | 10,051 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.